Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile

• Main Authors: Mariana Vieira Morau (Author), Cecilia Souto Seguin (Author), Mauricio Wesley Perroud Junior (Author), Carolina Dagli-Hernandez (Author), Eder de Carvalho Pincinato (Author), Patricia Moriel (Author)
• Format: Book
• Published: MDPI AG, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Gefitinib is a selective inhibitor of the epidermal growth factor receptor that is used to treat advanced and metastatic non-small cell lung cancer (NSCLC). Dermatological adverse reactions are most commonly associated with gefitinib treatment. The cause of adverse reactions in individuals is multif...